These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22107877)

  • 1. Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice.
    Merlo LJ; Greene WM; Pomm R
    J Addict Med; 2011 Dec; 5(4):279-83. PubMed ID: 22107877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.
    Aklin WM; Severtson SG; Umbricht A; Fingerhood M; Bigelow GE; Lejuez CW; Silverman K
    J Clin Psychiatry; 2012 Aug; 73(8):e1056-61. PubMed ID: 22967782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study.
    Rabinowitz J; Cohen H; Tarrasch R; Kotler M
    Drug Alcohol Depend; 1997 Aug; 47(2):77-86. PubMed ID: 9298329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term relapse of ultra-rapid opioid detoxification.
    Salimi A; Safari F; Mohajerani SA; Hashemian M; Kolahi AA; Mottaghi K
    J Addict Dis; 2014; 33(1):33-40. PubMed ID: 24471478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification].
    Jovanović T; Lazarević D; Nikolić G
    Vojnosanit Pregl; 2012 Apr; 69(4):326-32. PubMed ID: 22624424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients.
    Mysels DJ; Vosburg SK; Benga I; Levin FR; Sullivan MA
    J Opioid Manag; 2011; 7(1):47-53. PubMed ID: 21434584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problem drinking and low-dose naltrexone-assisted opioid detoxification.
    Mannelli P; Peindl K; Patkar AA; Wu LT; Tharwani HM; Gorelick DA
    J Stud Alcohol Drugs; 2011 May; 72(3):507-13. PubMed ID: 21513688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release naltrexone opioid treatment at jail reentry (XOR).
    McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
    Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals.
    Roth A; Hogan I; Farren C
    J Subst Abuse Treat; 1997; 14(1):19-22. PubMed ID: 9218232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
    Bahji A; Carlone D; Altomare J
    Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid-dependent error processing.
    Fellows-Smith J
    J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Naltrexone and opiate substitutive treatment].
    Dupouy J; Poutrain JC; Lapeyre-Mestre M
    Therapie; 2011; 66(6):549-52. PubMed ID: 22691393
    [No Abstract]   [Full Text] [Related]  

  • 14. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.
    Dunn KE; Defulio A; Everly JJ; Donlin WD; Aklin WM; Nuzzo PA; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Exp Clin Psychopharmacol; 2013 Feb; 21(1):74-83. PubMed ID: 23205722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One approach to the return to residency for anesthesia residents recovering from opioid addiction.
    Bryson EO; Levine A
    J Clin Anesth; 2008 Aug; 20(5):397-400. PubMed ID: 18761254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
    Poser W; Ehrenreich H
    Internist (Berl); 1996 Oct; 37(10):1061-7; discussion 1067. PubMed ID: 9019453
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.